These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 12903185)
41. Cloning and molecular characterization of telomerase reverse transcriptase (TERT) and telomere length analysis of Peromyscus leucopus. Zhao X; Ueda Y; Kajigaya S; Alaks G; Desierto MJ; Townsley DM; Dumitriu B; Chen J; Lacy RC; Young NS Gene; 2015 Aug; 568(1):8-18. PubMed ID: 25962353 [TBL] [Abstract][Full Text] [Related]
42. A novel platinum compound inhibits telomerase activity in vitro and reduces telomere length in a human hepatoma cell line. Furuta M; Nozawa K; Takemura M; Izuta S; Murate T; Tsuchiya M; Yoshida K; Taka N; Nimura Y; Yoshida S Int J Cancer; 2003 May; 104(6):709-15. PubMed ID: 12640677 [TBL] [Abstract][Full Text] [Related]
43. Pharmacological intervention strategies for affecting telomerase activity: future prospects to treat cancer and degenerative disease. Tárkányi I; Aradi J Biochimie; 2008 Jan; 90(1):156-72. PubMed ID: 17945408 [TBL] [Abstract][Full Text] [Related]
44. Telomeres and telomerases as drug targets. Rezler EM; Bearss DJ; Hurley LH Curr Opin Pharmacol; 2002 Aug; 2(4):415-23. PubMed ID: 12127874 [TBL] [Abstract][Full Text] [Related]
45. Implications of telomere-independent activities of telomerase reverse transcriptase in human cancer. Ding D; Zhou J; Wang M; Cong YS FEBS J; 2013 Jul; 280(14):3205-11. PubMed ID: 23527617 [TBL] [Abstract][Full Text] [Related]
46. A modified model for translocation events of processive nucleotide and repeat additions by the recombinant telomerase. Xie P Biophys Chem; 2010 Dec; 153(1):83-96. PubMed ID: 21055868 [TBL] [Abstract][Full Text] [Related]
47. [Telomere and telomerase as targets for anti-cancer drugs]. Ide T Nihon Rinsho; 2004 Jul; 62(7):1271-6. PubMed ID: 15283143 [TBL] [Abstract][Full Text] [Related]
48. Isothiazolone derivatives selectively inhibit telomerase from human and rat cancer cells in vitro. Hayakawa N; Nozawa K; Ogawa A; Kato N; Yoshida K; Akamatsu Ki; Tsuchiya M; Nagasaka A; Yoshida S Biochemistry; 1999 Aug; 38(35):11501-7. PubMed ID: 10471302 [TBL] [Abstract][Full Text] [Related]
49. A unique pause pattern during telomere addition by the error-prone telomerase from the ciliate Paramecium tetraurelia. Ye AJ; Romero DP Gene; 2002 Jul; 294(1-2):205-13. PubMed ID: 12234682 [TBL] [Abstract][Full Text] [Related]
50. Telomerase inhibitors and 'T-oligo' as cancer therapeutics: contrasting molecular mechanisms of cytotoxicity. Rankin AM; Faller DV; Spanjaard RA Anticancer Drugs; 2008 Apr; 19(4):329-38. PubMed ID: 18454043 [TBL] [Abstract][Full Text] [Related]
51. Detection of telomerase activity in Chinese hamster V79 cells and its inhibition by 7-deaza-deoxy guanosine triphosphate and (TTAGGG)4 in vitro. Pandit B; Bhattacharyya NP Biochem Biophys Res Commun; 1998 Oct; 251(2):620-4. PubMed ID: 9792823 [TBL] [Abstract][Full Text] [Related]
52. Thymol antifungal mode of action involves telomerase inhibition. Darvishi E; Omidi M; Bushehri AA; Golshani A; Smith ML Med Mycol; 2013 Nov; 51(8):826-34. PubMed ID: 23718894 [TBL] [Abstract][Full Text] [Related]
53. The telomere and telomerase: how Do they interact? Blackburn E Mt Sinai J Med; 1999; 66(5-6):292-300. PubMed ID: 10618727 [TBL] [Abstract][Full Text] [Related]
55. Potent inhibition of human telomerase by nitrostyrene derivatives. Kim JH; Kim JH; Lee GE; Lee JE; Chung IK Mol Pharmacol; 2003 May; 63(5):1117-24. PubMed ID: 12695540 [TBL] [Abstract][Full Text] [Related]
56. Telomeres and telomerase: Pharmacological targets for new anticancer strategies? Pendino F; Tarkanyi I; Dudognon C; Hillion J; Lanotte M; Aradi J; Ségal-Bendirdjian E Curr Cancer Drug Targets; 2006 Mar; 6(2):147-80. PubMed ID: 16529544 [TBL] [Abstract][Full Text] [Related]
57. Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. Tong W; Lu CD; Sharma SK; Matsuura S; So AG; Scott WA Biochemistry; 1997 May; 36(19):5749-57. PubMed ID: 9153415 [TBL] [Abstract][Full Text] [Related]
58. Inhibition of human telomerase by rubromycins: implication of spiroketal system of the compounds as an active moiety. Ueno T; Takahashi H; Oda M; Mizunuma M; Yokoyama A; Goto Y; Mizushina Y; Sakaguchi K; Hayashi H Biochemistry; 2000 May; 39(20):5995-6002. PubMed ID: 10821671 [TBL] [Abstract][Full Text] [Related]
59. Telomere inhibition and telomere disruption as processes for drug targeting. Rezler EM; Bearss DJ; Hurley LH Annu Rev Pharmacol Toxicol; 2003; 43():359-79. PubMed ID: 12540745 [TBL] [Abstract][Full Text] [Related]
60. Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway. Kelland L Clin Cancer Res; 2007 Sep; 13(17):4960-3. PubMed ID: 17785545 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]